Steering target selectivity and potency by fragment-based de novo drug design

Tiago Rodrigues, Takayuki Kudoh, Filip Roudnicky, Yi Fan Lim, Yen Chu Lin, Christian P. Koch, Masaharu Seno, Michael Detmar, Gisbert Schneider

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.

Original languageEnglish
Pages (from-to)10006-10009
Number of pages4
JournalAngewandte Chemie - International Edition
Volume52
Issue number38
DOIs
Publication statusPublished - Sep 16 2013

Fingerprint

Phosphotransferases
Lead
Ligands
Vascular Endothelial Growth Factor Receptor-2
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins

Keywords

  • drug design
  • drug discovery
  • fragment-based design
  • kinase inhibitors
  • VEGFR

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis

Cite this

Rodrigues, T., Kudoh, T., Roudnicky, F., Lim, Y. F., Lin, Y. C., Koch, C. P., ... Schneider, G. (2013). Steering target selectivity and potency by fragment-based de novo drug design. Angewandte Chemie - International Edition, 52(38), 10006-10009. https://doi.org/10.1002/anie.201304847

Steering target selectivity and potency by fragment-based de novo drug design. / Rodrigues, Tiago; Kudoh, Takayuki; Roudnicky, Filip; Lim, Yi Fan; Lin, Yen Chu; Koch, Christian P.; Seno, Masaharu; Detmar, Michael; Schneider, Gisbert.

In: Angewandte Chemie - International Edition, Vol. 52, No. 38, 16.09.2013, p. 10006-10009.

Research output: Contribution to journalArticle

Rodrigues, T, Kudoh, T, Roudnicky, F, Lim, YF, Lin, YC, Koch, CP, Seno, M, Detmar, M & Schneider, G 2013, 'Steering target selectivity and potency by fragment-based de novo drug design', Angewandte Chemie - International Edition, vol. 52, no. 38, pp. 10006-10009. https://doi.org/10.1002/anie.201304847
Rodrigues, Tiago ; Kudoh, Takayuki ; Roudnicky, Filip ; Lim, Yi Fan ; Lin, Yen Chu ; Koch, Christian P. ; Seno, Masaharu ; Detmar, Michael ; Schneider, Gisbert. / Steering target selectivity and potency by fragment-based de novo drug design. In: Angewandte Chemie - International Edition. 2013 ; Vol. 52, No. 38. pp. 10006-10009.
@article{d203815dbdbb481399f9f34469d51806,
title = "Steering target selectivity and potency by fragment-based de novo drug design",
abstract = "Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.",
keywords = "drug design, drug discovery, fragment-based design, kinase inhibitors, VEGFR",
author = "Tiago Rodrigues and Takayuki Kudoh and Filip Roudnicky and Lim, {Yi Fan} and Lin, {Yen Chu} and Koch, {Christian P.} and Masaharu Seno and Michael Detmar and Gisbert Schneider",
year = "2013",
month = "9",
day = "16",
doi = "10.1002/anie.201304847",
language = "English",
volume = "52",
pages = "10006--10009",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "38",

}

TY - JOUR

T1 - Steering target selectivity and potency by fragment-based de novo drug design

AU - Rodrigues, Tiago

AU - Kudoh, Takayuki

AU - Roudnicky, Filip

AU - Lim, Yi Fan

AU - Lin, Yen Chu

AU - Koch, Christian P.

AU - Seno, Masaharu

AU - Detmar, Michael

AU - Schneider, Gisbert

PY - 2013/9/16

Y1 - 2013/9/16

N2 - Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.

AB - Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.

KW - drug design

KW - drug discovery

KW - fragment-based design

KW - kinase inhibitors

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=84884215738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884215738&partnerID=8YFLogxK

U2 - 10.1002/anie.201304847

DO - 10.1002/anie.201304847

M3 - Article

VL - 52

SP - 10006

EP - 10009

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 38

ER -